Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | MPO | P05164 | 1/20 | 0.46 |
| ▸ | NPFFR1 | Q9GZQ6 | 1/20 | 0.46 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | DHODH | Q02127 | 2/20 | 0.43 |
| ▸ | FABP3 | P05413 | 1/20 | 0.43 |
| ▸ | FABP4 | P15090 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4744795 | 0.85 | POLB (0.68) | POLBNR4A2LMNAMPOALDH1A1 | |
| SCHEMBL3648083 | 0.81 | LMNA (0.72) | POLBNR4A2LMNAMPONPFFR1 | |
| SCHEMBL6481364 | 0.81 | POLB (0.72) | POLBNR4A2LMNAMPONPFFR1 | |
| SCHEMBL1241442 | 0.81 | ALDH1A1 (0.42) | POLBLMNAMPONPFFR1NPFFR2 | |
| SCHEMBL29589153 | 0.81 | POLB (0.72) | POLBNR4A2LMNAMPONPFFR1 | |
| SCHEMBL3760247 | 0.81 | LMNA (0.61) | LMNAALDH1A1MEN1KMT2AHTT | |
| SCHEMBL4966064 | 0.78 | ALDH1A1 (0.55) | MPOALDH1A1MEN1KMT2AHTT | |
| SCHEMBL6481363 | 0.78 | POLB (0.53) | POLBNR4A2LMNAMPONPFFR1 | |
| SCHEMBL3906125 | 0.78 | GAA (0.47) | LMNAMPOALDH1A1DHODHKDM4E | |
| SCHEMBL3642253 | 0.78 | LMNA (0.41) | POLBLMNAALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0124752-B1 | MIXTURES OF SUBSTANCES WITH GROWTH AND OUTPUT ACCELERATING EFFECT AS WELL AS FEED AND WATERING LIQUIDS WHICH CONTAIN LOW AMOUNTS OF THESE MIXTURES | BASF Aktiengesellschaft (DE) | 1986-07-16 | — | — | EP | claimed |
| US-4496727-A | ORGANIC PIGMENTS; PLASTICS; LACQUERS; INKS; COATINGS; COLOR FASTNESS | CIBA-GEIGY CORPORATION (US) | 1985-01-29 | — | — | US | claimed |
| EP-0065192-B1 | GROWTH-PROMOTING FODDER OR DRINKING LIQUID | BASF Aktiengesellschaft (DE) | 1984-02-01 | — | — | EP | claimed |
| EP-4514791-A1 | SUBSTITUTED 6- (PYRIMIDIN-4-YL) QUINOLINE COMPOUNDS AS CYCLIN DEPENDENT KINASE INHIBITORS | BeiGene, Ltd. (KY) | 2025-03-05 | — | — | EP | disclosed |
| US-20250026769-A1 | PAPD5 INHIBITORS AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2025-01-23 | — | — | US | disclosed |
| CN-119095840-A | Substituted 6- (pyrimidin-4-yl) quinoline compounds as cyclin dependent kinase inhibitors | 百济神州有限公司 | 2024-12-06 | — | — | CN | disclosed |
| US-20240300937-A1 | Substituted 6-(Pyrimidin-4-yl)Quinoline Compounds as Cyclin Dependent Kinase Inhibitors | BEIGENE, LTD. (KY) | 2024-09-12 | — | — | US | disclosed |
| EP-4423081-A2 | PAPD5 INHIBITORS AND METHODS OF USE THEREOF | The Children's Medical Center Corporation (US) | 2024-09-04 | — | — | EP | disclosed |
| CN-118201920-A | PAPD5 inhibitors and methods of use thereof | 儿童医疗中心公司 | 2024-06-14 | — | — | CN | disclosed |
| WO-2023208173-A1 | SUBSTITUTED 6- (PYRIMIDIN-4-YL) QUINOLINE COMPOUNDS AS CYCLIN DEPENDENT KINASE INHIBITORS | BEIGENE , LTD. (KY) | 2023-11-02 | — | — | WO | disclosed |
| WO-2023086220-A2 | PAPD5 INHIBITORS AND METHODS OF USE THEREOF | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2023-05-19 | — | — | WO | disclosed |
| WO-2023086220-A2 | PAPD5 INHIBITORS AND METHODS OF USE THEREOF | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2023-05-19 | — | — | WO | disclosed |
| WO-2008117079-A1 | ANTIMICROBIAL COMPOUNDS BASED UPON 4-AMINOQUINOLINE | HELPERBY THERAPEUTICS LIMITED (GB) | 2008-10-02 | — | — | WO | disclosed |
| EP-0113432-B1 | CHLOROMETHYL QUINOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE | ALKALOIDA VEGYéSZETI GYáR (HU) | 1993-03-17 | — | — | EP | disclosed |
| US-4496727-A | ORGANIC PIGMENTS; PLASTICS; LACQUERS; INKS; COATINGS; COLOR FASTNESS | CIBA-GEIGY CORPORATION (US) | 1985-01-29 | — | — | US | disclosed |
| EP-0113432-A1 | Chloromethyl quinoline derivatives, process for their preparation and their use | ALKALOIDA VEGYéSZETI GYáR (HU) | 1984-07-18 | — | — | EP | disclosed |
| US-4385174-A | FOR PIGMENTS | CIBA-GEIGY CORPORATION (US) | 1983-05-24 | — | — | US | disclosed |
| EP-0036388-A2 | Isoindoline derivatives, process for their preparation and their use | CIBA-GEIGY AG (CH) | 1981-09-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240300937-A1 | Substituted 6-(Pyrimidin-4-yl)Quinoline Compounds as Cyclin Dependent Kinase Inhibitors | CDK4, CDK6, CDK2 | POLB 648/4885NR4A2 800/4885LMNA 2157/4885 |
| US-20250026769-A1 | PAPD5 INHIBITORS AND METHODS OF USE THEREOF | POT1, PARP15, TERT | POLB 287/4885NR4A2 3583/4885LMNA 1126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.